Compare BRID & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ATYR |
|---|---|---|
| Founded | 1932 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 49.2M |
| IPO Year | 1995 | 2015 |
| Metric | BRID | ATYR |
|---|---|---|
| Price | $5.79 | $0.36 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 3.4K | ★ 728.9K |
| Earning Date | 06-01-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $5.76 | $0.37 |
| 52 Week High | $8.62 | $1.12 |
| Indicator | BRID | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 25.85 |
| Support Level | N/A | N/A |
| Resistance Level | $6.33 | $0.59 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.48 | 2.13 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).